Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 05, 2021 07:30 ET | Source: Immunovant

Immunovant Reports Financial Results for the Quarter Ended September 30, 2021

NEW YORK, Nov. 05, 2021 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company focused on enabling normal lives for people with autoimmune diseases, today...
September 27, 2021 08:00 ET | Source: Immunovant

Immunovant to Participate in Roivant R&D Day 2021

NEW YORK, Sept. 27, 2021 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company focused on enabling normal lives for people with autoimmune diseases, today...
September 15, 2021 07:00 ET | Source: Immunovant

Immunovant Appoints Renee Barnett as Chief Financial Officer

Ms. Barnett brings a wealth of financial experience to ImmunovantExpands executive leadership team as Immunovant plans to return to the clinic across multiple indications NEW YORK, Sept. 15, 2021 ...
August 09, 2021 06:30 ET | Source: Immunovant

Immunovant Reports Financial Results for the Quarter Ended June 30, 2021

NEW YORK, Aug. 09, 2021 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company focused on enabling normal lives for people with autoimmune diseases, today...
August 06, 2021 16:22 ET | Source: Immunovant

Immunovant to Report Financial Results for Quarter Ended June 30, 2021

NEW YORK, Aug. 06, 2021 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company focused on enabling normal lives for people with autoimmune diseases, today...
August 02, 2021 07:30 ET | Source: Immunovant

Immunovant Receives $200 Million Strategic Investment from Roivant Sciences

Proceeds will fund continued development of IMVT-1401 in multiple indications NEW YORK, Aug. 02, 2021 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company...
June 01, 2021 07:31 ET | Source: Immunovant

Immunovant Provides Corporate Updates and Reports Financial Results for the Quarter and Fiscal Year Ended March 31, 2021

Immunovant plans to resume clinical development of IMVT-1401 in Myasthenia Gravis (MG) and Warm Autoimmune Hemolytic Anemia (WAIHA) as well as initiate two additional mid-to-late stage studies in the...
February 16, 2021 08:00 ET | Source: Immunovant

Immunovant Reports Financial Results for the Quarter and Nine Months Ended December 31, 2020

NEW YORK, Feb. 16, 2021 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company focused on enabling normal lives for patients with autoimmune diseases, today...
February 02, 2021 06:30 ET | Source: Immunovant

Immunovant Announces Voluntary Pause in Clinical Dosing of IMVT-1401

NEW YORK, Feb. 02, 2021 (GLOBE NEWSWIRE) -- Immunovant (Nasdaq: IMVT), a clinical-stage biopharmaceutical company focused on enabling normal lives for patients with autoimmune diseases, today...
January 12, 2021 17:00 ET | Source: Immunovant

Immunovant Appoints Rita Jain Chief Medical Officer And Provides Corporate Update

Dr. Jain brings deep expertise in the design and execution of complex clinical trials, having overseen the development of more than 15 new chemical entities and marketed productsDr. Jain’s broad and...